Search

This presentation is an excerpt from the ALF 2021 Poster Competition and showcases posters and a brief video created by early career investigators.

This presentation is an excerpt from the ALF 2021 Poster Competition and showcases posters and a brief video created by early career investigators.

As incredible as it may seem in pure numbers, Nonalcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States.

NAFLD is the most common liver disease in the United States. It is thought to affect approximately 30 million people, 8.6 million of whom have the more severe form of the disease, NASH.

Fatty liver disease is when there is excess fat in the liver. This fat can be associated with inflammation or can just be isolated fat in the liver.

Presented by Dr. Wajahat Mehal, Professor of Medicine and Director of the Yale Weight Loss Program and Jessica Dean, Registered Dietician, Yale New Haven Health’s Fatty Liver Clinic.

Award-winning dietitian Kristin Kirkpatrick and hepatologist Dr. Ibrahim Hanouneh have teamed up for a life-changing program that will help you achieve optimal health.

First drug therapy treatment for nonalcoholic steatohepatitis (NASH) provides hopes to millions of Americans

Bruce Dimmig, motivated ALF Advocacy Ambassador and volunteer extraordinaire, has been living with the uncertainties of life with a rare liver disease for more than a decade and a half. Read about his story and how his persistence helped him get to a working diagnosis nearly ten years later.

Research topics include fatty liver disease, rare and pediatric liver disease, liver cancer, cirrhosis and more

Dr. Lazarus honored for his extensive contributions to viral hepatitis, steatotic liver disease and global health.

The one-day virtual event brings together patients, caregivers, leading medical experts and researchers.